Reed W Kamyszek1,2, Matthew W Foster3, Brooke A Evans2, Keaton Stoner4, Jessica Poisson5, Amudan J Srinivasan6, J Will Thompson3, M Arthur Moseley3, Micah J Mooberry7, Ian J Welsby8. 1. Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States of America. 2. Duke University School of Medicine, Durham, NC, United States of America. 3. Duke Proteomics and Metabolomics Shared Resource, Durham, NC, United States of America. 4. Duke University Department of Biology, Durham, NC, United States of America. 5. Department of Pathology, Duke University Medical Center, Durham, NC, United States of America. 6. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America. 7. Department of Medicine, University of North Carolina Medical Center, Chapel Hill, NC, United States of America. 8. Department of Anesthesiology, Duke University Medical Center, Durham, NC, United States of America.
Abstract
BACKGROUND: As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo. MATERIALS AND METHODS: Whole blood (WB)- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT® Blood System (Cerus Corporation, Concord, CA, USA) and cryo was prepared from treated plasma. Protein levels in PI-cryo and paired controls were quantified using liquid chromatography-tandem mass spectrometry. Functional haemostatic properties of PI-cryo were assessed using a microparticle (MP) prothrombinase assay, thrombin generation assay, and an in vitro coagulopathy model subjected to thromboelastometry. RESULTS: Over 300 proteins were quantified across paired PI-cryo and controls. PI did not alter the expression of coagulation factors, but levels of platelet-derived proteins and platelet-derived MPs were markedly lower in the WB PI-cryo group. Compared to controls, WB (but not APH) cryo samples demonstrated significantly lower MP prothrombinase activity, prolonged clotting time, and lower clot firmness on thromboelastometry after PI. However, PI did not affect overall thrombin generation variables in either group. DISCUSSION: Data from this study suggest that PI via INTERCEPT® Blood System does not significantly impact the coagulation factor content or function of cryo but reduces the higher MP content in WB-derived cryo. PI-cryo products may confer benefits in reducing pathogen transmission without affecting haemostatic function, but further in vivo assessment is warranted.
BACKGROUND: As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo. MATERIALS AND METHODS: Whole blood (WB)- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT® Blood System (Cerus Corporation, Concord, CA, USA) and cryo was prepared from treated plasma. Protein levels in PI-cryo and paired controls were quantified using liquid chromatography-tandem mass spectrometry. Functional haemostatic properties of PI-cryo were assessed using a microparticle (MP) prothrombinase assay, thrombin generation assay, and an in vitro coagulopathy model subjected to thromboelastometry. RESULTS: Over 300 proteins were quantified across paired PI-cryo and controls. PI did not alter the expression of coagulation factors, but levels of platelet-derived proteins and platelet-derived MPs were markedly lower in the WB PI-cryo group. Compared to controls, WB (but not APH) cryo samples demonstrated significantly lower MP prothrombinase activity, prolonged clotting time, and lower clot firmness on thromboelastometry after PI. However, PI did not affect overall thrombin generation variables in either group. DISCUSSION: Data from this study suggest that PI via INTERCEPT® Blood System does not significantly impact the coagulation factor content or function of cryo but reduces the higher MP content in WB-derived cryo. PI-cryo products may confer benefits in reducing pathogen transmission without affecting haemostatic function, but further in vivo assessment is warranted.
Authors: Anna Ettinger; Meghan M Miklauz; David J Bihm; Gabriela Maldonado-Codina; Raymond P Goodrich Journal: Transfus Apher Sci Date: 2012-02-17 Impact factor: 1.764
Authors: John B Holcomb; Erin E Fox; Xuan Zhang; Nathan White; Charles E Wade; Bryan A Cotton; Deborah J del Junco; Eileen M Bulger; Mitchell J Cohen; Martin A Schreiber; John G Myers; Karen J Brasel; Herb A Phelan; Louis H Alarcon; Peter Muskat; Mohammad H Rahbar Journal: J Trauma Acute Care Surg Date: 2013-07 Impact factor: 3.313
Authors: Melissa M Cushing; Lars M Asmis; Rebecca M Harris; Robert A DeSimone; Shanna Hill; Natalia Ivascu; Thorsten Haas Journal: Transfusion Date: 2019-02-04 Impact factor: 3.157
Authors: N Curry; C Rourke; R Davenport; S Beer; L Pankhurst; A Deary; H Thomas; C Llewelyn; L Green; H Doughty; G Nordmann; K Brohi; S Stanworth Journal: Br J Anaesth Date: 2015-05-19 Impact factor: 9.166